BP1.4979

BP1.4979
Clinical data
Other namesBP-1.4979; BP14979; BP-14979
Routes of
administration		Oral
Drug classDopamine D3 receptor agonist
Pharmacokinetic data
Onset of action1 hour (TmaxTooltip time to peak levels)
Elimination half-life8 hours
Identifiers
  • N-[4-[2-[4-(3-cyanophenyl)piperazin-1-yl]ethyl]cyclohexyl]-3-methoxypropanamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC23H34N4O2
Molar mass398.551 g·mol−1
3D model (JSmol)
  • COCCC(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=CC=CC(=C3)C#N
  • InChI=1S/C23H34N4O2/c1-29-16-10-23(28)25-21-7-5-19(6-8-21)9-11-26-12-14-27(15-13-26)22-4-2-3-20(17-22)18-24/h2-4,17,19,21H,5-16H2,1H3,(H,25,28)
  • Key:PLMAPPWZOQMTBI-UHFFFAOYSA-N

BP1.4979 is a selective dopamine D3 receptor agonist which is under development for the treatment of binge-eating disorder, obsessive–compulsive disorder (OCD), restless legs syndrome (RLS), and smoking withdrawal. It is taken orally. The drug acts as a highly potent weak partial agonist of the dopamine D3 receptor (Ki = ~1 nM; EC50Tooltip half-maximal effective concentration = 0.7 nM; EmaxTooltip maximal efficacy = 32%). It has around 200-fold higher affinity for the dopamine D3 receptor than for the dopamine D2 receptor (Ki = 192 nM), where it is an antagonist. BP1.4979 showed 66% dopamine D3 receptor occupancy and 8% dopamine D2 receptor occupancy with positron emission tomography (PET) imaging in a clinical study. The time to peak levels of BP1.4979 is 1 hour and its elimination half-life is about 8 hours. The drug is under development by Bioprojet. As of January 2026, it is in phase 2 clinical trials for all indications.

See also

References

  1. 1 2 3 4 5 "BP 14979". AdisInsight. 16 January 2026. Retrieved 18 January 2026.
  2. 1 2 3 4 5 6 7 Di Ciano P, Mansouri E, Tong J, Wilson AA, Houle S, Boileau I, et al. (June 2019). "Occupancy of dopamine D2 and D3 receptors by a novel D3 partial agonist BP1.4979: a [11C]-(+)-PHNO PET study in humans". Neuropsychopharmacology. 44 (7): 1284–1290. doi:10.1038/s41386-018-0285-4. PMC 6785153. PMID 30659274. The purpose of the present study was to investigate, for the first time in healthy controls, the in vivo occupancy of the DRD3 and DRD2 by a selective DRD3 partial agonist. BP1.4979 has an affinity for the human DRD3 of ~1 nM and presents a partial agonist behaviour with an intrinsic activity of 32% ± 2.6% and EC50 of 0.7 ± 0.3 nM. In contrast, it behaves as an antagonist at the hDRD2 with Ki of 192 nM. After oral administration in humans, it reaches peak serum concentrations in one hour and has a half-life of about 8 h.
  3. 1 2 Sokoloff P, Le Foll B (2022). "A Historical Perspective on the Dopamine D3 Receptor". Therapeutic Applications of Dopamine D3 Receptor Function. Current Topics in Behavioral Neurosciences. Vol. 60. Cham: Springer International Publishing. pp. 1–28. doi:10.1007/7854_2022_315. ISBN 978-3-031-23057-8. PMID 35467293. Retrieved 18 January 2026.